2-ethyl-4,4-dimethylimidazoline | 1349701-46-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 亚胺内酰胺
• 英文名称: 2-ethyl-4,4-dimethylimidazoline
• 英文别名: 2-Ethyl-5,5-dimethyl-1,4-dihydroimidazole
• CAS: 1349701-46-7
• 化学式: C₇H₁₄N₂
• 分子量: 126.202
• InChiKey: OIWRDWSSCHEIMA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  24.4
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  1-bromo-1-octyne 、 2-ethyl-4,4-dimethylimidazoline 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (Z)-1-(1-bromo-1-octen-2-yl)-2-ethyl-4,4-dimethylimidazoline 、 (Z)-1-(1-bromo-1-octen-2-yl)-2-ethyl-5,5-dimethylimidazoline
  参考文献：
  名称：

  Additive-Free Nucleophilic Addition of Imidazolines and Imidazoles to Haloacetylenes

  摘要：

  Nucleophilic addition of imidazolines to 1-halo-1-aikres takes place by simple heating in DMF without any additives to give (Z)-N-(1-hato-1-alken-2-yl)imidazolines in good yield and in a highly regio- and stereoselective manner. These reaction conditions are also valid for the similar addition of imidazoles.

  DOI：

  10.1021/ol2027448

文献信息

• PD-1/PD-L1 inhibitors
  申请人：Gilead Sciences, Inc.

  公开号：US10710986B2

  公开（公告）日：2020-07-14

  Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.

  本研究公开了式（I）化合物、单独使用所述化合物或将其与其他制剂结合使用的方法以及所述化合物用于治疗癌症的组合物。
• PD-1/PD-L1 INHIBITORS
  申请人：Gilead Sciences, Inc.

  公开号：US20190270727A1

  公开（公告）日：2019-09-05

  Compounds of Formula (I), methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
• Additive-Free Nucleophilic Addition of Imidazolines and Imidazoles to Haloacetylenes
  作者：Masahito Yamagishi、Jun Okazaki、Ken Nishigai、Takeshi Hata、Hirokazu Urabe

  DOI：10.1021/ol2027448

  日期：2012.1.6

  Nucleophilic addition of imidazolines to 1-halo-1-aikres takes place by simple heating in DMF without any additives to give (Z)-N-(1-hato-1-alken-2-yl)imidazolines in good yield and in a highly regio- and stereoselective manner. These reaction conditions are also valid for the similar addition of imidazoles.